← Leaderboards
Behnam Ebrahimi
University Of Texas Hlth Science Center
$173,743
Attributed
$173,743
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $100.9K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$173,743 · 2
By mechanism
K00$100,923 · 1
F99$72,820 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Suryavathi Viswanadhapalli$873,997
- Ganesh V Halade$4,870,615
Others in their field
Other Rising Stars on “Targeted Treatment”
- Suma Babu · Massachusetts General Hospital$25,017,559
- Sabrina Paganoni · Massachusetts General Hospital$25,017,559
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- John Alam · Eip Pharma, Inc.$10,411,018
- Jeff T Hutchins · Inhalon Biopharma, Inc.$9,162,425
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
Research focus
Targeted TreatmentNew Therapeutic TargetInhibitorStandard Of CareTherapy ResistantOperative Surgical ProceduresGeneticHypoxiaPathway InteractionsResistanceTumorUnited StatesCancer CellCellsChemotherapyColorectal CancerGenomic ApproachCaringCancer RecurrenceCancer PatientAutocrine CommunicationAngiogenesis InhibitorsAutocrineChemotherapy-Oncologic Procedure
Grant awards (3)
Identifying Mechanisms of Resistance to SLC6AB Inhibition in CRC Liver Metastasis$100,923
K00 · FY2025 · CA · contact PI
Targeting chemotherapy resistant high grade serous ovarian cancer$36,300
F99 · FY2024 · CA · contact PI
Targeting chemotherapy resistant high grade serous ovarian cancer$36,520
F99 · FY2023 · CA · contact PI